These results provide direct evidence that candesartan, a drug that inhibits obesity-associated intracellular Ca2+ overload, ameliorates obesity-induced insulin resistance by enhancing the postprandial membrane localization of AKT PH domains, leading to improved insulin sensitivity and signaling. The gene discussed is AKT1; the disease is obesity due to melanocortin 4 receptor deficiency.